Fig. 3.

Unique activation of different signaling pathways in metastatic pancreatic cancer revealed by quantitative tyrosine phosphoproteomics analysis. A, a pattern of tyrosine phosphorylation levels among pancreatic cancer metastases was briefly screened via Western blot experiment using anti-phosphotyrosine antibody. B, schematics of SILAC-based quantitative tyrosine phosphoproteomics of multiple pancreatic cancer metastases. Tyrosine phosphorylated peptides were enriched via immunoaffinity purification using anti-phosphotyrosine antibodies. C, the pie chart shows that a greater portion (∼89%) of identified tyrosine phosphorylation sites was found to be altered.